MedTrace Logo

Neoadjuvant Chemotherapy and Radical Surgery in Stage IIB Cervical Cancer

NCT02595554 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2017-02-03

No results posted yet for this study

Summary

Neoadjuvant chemotherapy (NACT) and radical surgery (RS) may have a possible better outcome to concurrent chemoirradiation (CCRT) in stage IIB cervical cancer. We try to verify such a hypothesis in terms of survival and treatment related morbidity.

Conditions

  • Cervical Carcinoma Stage IIB

Interventions

RADIATION

Concurrent chemoirradiation

External beam radiation therapy (EBRT) with concurrent weekly platinum chemotherapy followed by brachytherapy

DRUG

Paclitaxel

New adjuvant chemotherapy 3 cycles with Paclitaxel 150mg/m2 over 3 hours and Cisplatin

PROCEDURE

Radical Surgery

Radical hysterectomy (Type III or Type IV hysterectomy) plus bilateral pelvic lymph node dissection and para-aortic lymph node dissection or sampling

DRUG

Cisplatin

New adjuvant chemotherapy 3 cycles with Paclitaxel and Cisplatin 70mg/m2

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Jihong Liu, Ph. D · Sun Yat-sen University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02595554 on ClinicalTrials.gov